

G I Hackett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8173611/publications.pdf>

Version: 2024-02-01

65
papers

2,526
citations

249298

26
h-index

223390

49
g-index

69
all docs

69
docs citations

69
times ranked

2380
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Testosterone on Hospital Admission with COVID-19 Infection Is Associated with Increased Mortality. <i>Androgens: Clinical Research and Therapeutics</i> , 2022, 3, 14-21.	0.2	2
2	Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. <i>The Lancet Healthy Longevity</i> , 2022, 3, e381-e393.	2.0	39
3	Lessons learnt from the variation across 6741 family/general practices in England in the use of treatments for hypogonadism. <i>Clinical Endocrinology</i> , 2021, 94, 827-836.	1.2	4
4	Testosterone Therapy in Adult-Onset Testosterone Deficiency: Hematocrit and Hemoglobin Changes. <i>Androgens: Clinical Research and Therapeutics</i> , 2021, 2, 141-149.	0.2	0
5	Is a fasting testosterone level really necessary for the determination of androgen status in men?. <i>Clinica Chimica Acta</i> , 2021, 521, 64-69.	0.5	6
6	Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: a prospective cohort study. <i>Cardiovascular Endocrinology and Metabolism</i> , 2021, 10, 37-44.	0.5	11
7	Testosterone Therapy: Increase in Hematocrit is Associated with Decreased Mortality. <i>Androgens: Clinical Research and Therapeutics</i> , 2021, 2, 150-159.	0.2	2
8	Important lessons about testosterone therapy- weight loss vs. testosterone therapy for symptom resolution, classical vs. functional hypogonadism, and shortterm vs. lifelong testosterone therapy. <i>Ageing Male</i> , 2020, 23, 585-591.	0.9	5
9	Hypogonadism is not being sufficiently recognised in 99% of general practices/family doctor surgeries. <i>International Journal of Clinical Practice</i> , 2020, 74, e13445.	0.8	2
10	Erectile dysfunction: is the NHS men's health friendly?. <i>Trends in Urology & Men's Health</i> , 2020, 11, 6-12.	0.2	2
11	An audit of the measurement and reporting of male testosterone levels in UK clinical biochemistry laboratories. <i>International Journal of Clinical Practice</i> , 2020, 74, e13607.	0.8	15
12	COVID-19, Type 2 Diabetes, and Hypogonadism: Lessons for Acute Management and Long-Term Prevention. <i>Androgens: Clinical Research and Therapeutics</i> , 2020, 1, 22-31.	0.2	2
13	Testosterone deficiency in men infected with COVID-19. <i>Trends in Urology & Men's Health</i> , 2020, 11, 7-10.	0.2	5
14	The treatment rate of erectile dysfunction (ED) in younger men with type 2 diabetes is up to four times higher than the equivalent non-diabetes population. <i>International Journal of Clinical Practice</i> , 2020, 74, e13538.	0.8	1
15	Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. <i>Andrology</i> , 2020, 8, 1222-1232.	1.9	3
16	New testosterone 2% gel using Ferring Advanced Skin Technology (FAST), for the treatment of testosterone deficiency in men, with a novel applicator. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 217-226.	1.2	0
17	Long-Term Testosterone Therapy in Type 2 Diabetes Is Associated with Decreasing Waist Circumference and Improving Erectile Function. <i>World Journal of Men's Health</i> , 2020, 38, 68.	1.7	18
18	Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?. <i>World Journal of Men's Health</i> , 2020, 38, 271.	1.7	13

#	ARTICLE	IF	CITATIONS
19	The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 591-599.	1.5	5
20	Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine. <i>Sexual Medicine Reviews</i> , 2019, 7, 636-649.	1.5	48
21	Sex Hormone Binding Globulin: A Review of its Interactions With Testosterone and Age, and its Impact on Mortality in Men With Type 2 Diabetes. <i>Sexual Medicine Reviews</i> , 2019, 7, 669-678.	1.5	23
22	Type 2 Diabetes and Testosterone Therapy. <i>World Journal of Men's Health</i> , 2019, 37, 31.	1.7	27
23	Paediatric and adult-onset male hypogonadism. <i>Nature Reviews Disease Primers</i> , 2019, 5, 38.	18.1	153
24	Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. <i>Sexual Medicine Reviews</i> , 2019, 7, 476-490.	1.5	24
25	Testosterone Therapy: An Assessment of the Clinical Consequences of Changes in Hematocrit and Blood Flow Characteristics. <i>Sexual Medicine Reviews</i> , 2019, 7, 650-660.	1.5	8
26	Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. <i>BJU International</i> , 2019, 123, 519-529.	1.3	31
27	Testosterone and the Heart. <i>European Cardiology Review</i> , 2019, 14, 103-110.	0.7	39
28	Erectile dysfunction and testosterone deficiency as cardiovascular risk factors?. <i>International Journal of Clinical Practice</i> , 2018, 72, e13054.	0.8	9
29	Screening for Hypogonadism in Primary Healthcare: How to do this Effectively. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2018, 126, 176-181.	0.6	1
30	British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men 2017. <i>Journal of Sexual Medicine</i> , 2018, 15, 430-457.	0.3	91
31	Managing Clinical Heterogeneity: An Argument for Benefit-Based Action Limits. <i>Journal of Engineering and Science in Medical Diagnostics and Therapy</i> , 2018, 1, .	0.3	4
32	The association of sex hormone-binding globulin with mortality is mediated by age and testosterone in men with type 2 diabetes. <i>Andrology</i> , 2018, 6, 846-853.	1.9	10
33	A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 375-386.	1.0	19
34	The Graham Jackson Memorial Lecture ISSM 2016 "The Man Who Knew Too Much": Time to Recognize Erectile Dysfunction and Low Testosterone as Independent Risk Factors for Cardiovascular Disease. <i>Sexual Medicine Reviews</i> , 2017, 5, 256-265.	1.5	12
35	UK policy statements on testosterone deficiency. <i>International Journal of Clinical Practice</i> , 2017, 71, e12901.	0.8	8
36	Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. <i>Andrology</i> , 2017, 5, 905-913.	1.9	19

#	ARTICLE	IF	CITATIONS
37	British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, with Statements for UK Practice. <i>Journal of Sexual Medicine</i> , 2017, 14, 1504-1523.	0.3	94
38	Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. <i>World Journal of Diabetes</i> , 2017, 8, 104.	1.3	36
39	Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. <i>Heart</i> , 2016, 102, 1750-1756.	1.2	74
40	An update on the role of testosterone replacement therapy in the management of hypogonadism. <i>Therapeutic Advances in Urology</i> , 2016, 8, 147-160.	0.9	21
41	Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. <i>BJU International</i> , 2016, 118, 804-813.	1.3	45
42	Fundamental Concepts Regarding Testosterone Deficiency and Treatment. <i>Mayo Clinic Proceedings</i> , 2016, 91, 881-896.	1.4	88
43	Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. <i>International Journal of Clinical Practice</i> , 2016, 70, 244-253.	0.8	76
44	Cancer, Benign Gynecology, and Sexual Function—Issues and Answers. <i>Journal of Sexual Medicine</i> , 2016, 13, 519-537.	0.3	11
45	Testosterone Replacement Therapy and Mortality in Older Men. <i>Drug Safety</i> , 2016, 39, 117-130.	1.4	23
46	Controversies in the diagnosis and management of testosterone deficiency syndrome. <i>Cmaj</i> , 2015, 187, 1342-1344.	0.9	1
47	Commentary on "Late-onset hypogonadism - beyond testosterone". <i>Asian Journal of Andrology</i> , 2015, 17, 334.	0.8	1
48	Testosterone Deficiency, Cardiac Health, and Older Men. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-10.	0.6	14
49	Testosterone Replacement Therapy Improves Metabolic Parameters in Hypogonadal Men with Type 2 Diabetes but Not in Men with Coexisting Depression: The BLAST Study. <i>Journal of Sexual Medicine</i> , 2014, 11, 840-856.	0.3	123
50	The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). <i>International Journal of Clinical Practice</i> , 2014, 68, 203-215.	0.8	81
51	Testosterone replacement therapy and cardiovascular events. <i>BMJ</i> , 2014, 349, g7230-g7230.	3.0	2
52	All Men with Vasculogenic Erectile Dysfunction Require a Cardiovascular Workup. <i>American Journal of Medicine</i> , 2014, 127, 174-182.	0.6	74
53	Testosterone Supplementation and Sexual Function: A Meta-Analysis Study. <i>Journal of Sexual Medicine</i> , 2014, 11, 1577-1592.	0.3	195
54	The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. <i>International Journal of Clinical Practice</i> , 2013, 67, 1163-1172.	0.8	48

#	ARTICLE	IF	CITATIONS
55	Testosterone Replacement Therapy with Long-Acting Testosterone Undecanoate Improves Sexual Function and Quality of Life Parameters vs. Placebo in a Population of Men with Type 2 Diabetes. <i>Journal of Sexual Medicine</i> , 2013, 10, 1612-1627.	0.3	127
56	Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. <i>International Journal of Clinical Practice</i> , 2013, 67, 606-618.	0.8	63
57	The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2012, 87, 766-778.	1.4	403
58	Testosterone and the heart. <i>International Journal of Clinical Practice</i> , 2012, 66, 648-655.	0.8	9
59	Services for erectile dysfunction in the UK - a 12-month review of referrals to a west Midlands NHS clinic. <i>International Journal of Clinical Practice</i> , 2010, 64, 925-929.	0.8	2
60	The burden and extent of comorbid conditions in patients with erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2009, 63, 1205-1213.	0.8	48
61	PDE5 inhibitors in diabetic peripheral neuropathy. <i>International Journal of Clinical Practice</i> , 2006, 60, 1123-1126.	0.8	30
62	ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Psychosocial Outcomes and Drug Attributes Affecting Treatment Choice in Men Receiving Sildenafil Citrate and Tadalafil for the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Open-Label, Crossover Study. <i>Journal of Sexual Medicine</i> , 2006, 3, 650-661.	0.3	50
63	ORIGINAL RESEARCH—COUPLES™ SEXUAL DYSFUNCTION: Vardenafil Improves Sexual Function and Treatment Satisfaction in Couples Affected by Erectile Dysfunction (ED): A Randomized, Double-Blind, Placebo-Controlled Trial in PDE5 Inhibitor-Naïve Men with ED and Their Partners. <i>Journal of Sexual Medicine</i> , 2006, 3, 1028-1036.	0.3	46
64	Managing erectile dysfunction. <i>Practitioner</i> , 2001, 245, 820, 823-4, 827-8.	0.3	0
65	Managing erectile dysfunction. <i>Practitioner</i> , 1998, 242, 632-6.	0.3	1